Utilization of capecitabine-oxaliplatin (CAPOX) versus infusional 5-fluorouracil and oxaliplatin (FFOX) in the adjuvant treatment (AT) of resected high-risk colon cancer.

被引：0
|
作者：
Sha, Aaron
Abadi, Shirin
Gill, Sharlene
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14696
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14696
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
    Porschen, Rainer
    Kubicka, S.
    Grothey, A.
    Grateven, U.
    Kretzschmar, A.
    Greil, R.
    Freier, W.
    Seufferlein, T.
    Arkenau, Ht
    Hinke, A.
    Schmoll, Hj
    Schmiegel, W.
    GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
  • [2] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [3] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    ANNALS OF ONCOLOGY, 2005, 16 : 283 - 283
  • [4] Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers
    Ramaswamy, Anant
    Bhargava, Prabhat
    Dubashi, Biswajit
    Gupta, Anuj
    Kapoor, Akhil
    Srinivas, Sujay
    Shetty, Omshree
    Jadhav, Poonam
    Desai, Veena
    Noronha, Vanita
    Joshi, Amit
    Menon, Nandini
    Patil, Vijay M.
    Mishra, Bal Krishna
    Sansar, Bipinesh
    Singh, Arpita
    Patel, Swapnil
    Singh, Satyendra Narayan
    Dhal, Ipsita
    Vinayak, Kunal Ranjan
    Pal, Vikash
    Mandavkar, Sarika
    Kannan, Sadhana
    Chaugule, Deepali
    Patil, Rajshree
    Parulekar, Manali
    Nashikkar, Chaitali
    Ankathi, Suman Kumar
    Kaushal, Rajiv Kumar
    Shah, Aekta
    Ganesan, Prasanth
    Kayal, Smita
    Ananthakrishnan, Ramesh
    Syed, Noorzia
    Samaddar, Debdeep
    Kapu, Venkatesh
    Shah, Anokhi
    Kaaviya, D.
    Suganiya, R.
    Srinivasan, Nirmala Devi
    Prabhash, Kumar
    Ostwal, Vikas
    JNCI CANCER SPECTRUM, 2024, 8 (04)
  • [5] Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study
    Sha, Aaron
    Abadi, Shirin
    Gill, Sharlene
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (07) : 501 - 506
  • [6] Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients
    Droz, JP
    Muracciole, X
    Mottet, N
    Kaci, MO
    Vannetzel, JM
    Albin, N
    Culine, S
    Rodier, JM
    Misset, JL
    Mackenzie, S
    Cvitkovic, E
    Benoit, G
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1291 - 1298
  • [7] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Seufferlein, T
    Reichardt, P
    Freier, W
    Graeven, U
    Grothey, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [8] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Jeong Eun Kim
    Yong Sang Hong
    Hwa Jung Kim
    Kyu-pyo Kim
    Sun Young Kim
    Seok-Byung Lim
    In Ja Park
    Chan Wook Kim
    Yong Sik Yoon
    Chang Sik Yu
    Jin Cheon Kim
    Ji Hun Kim
    Tae Won Kim
    Annals of Surgical Oncology, 2017, 24 : 1289 - 1294
  • [9] Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)
    Kim, Jeong Eun
    Hong, Yong Sang
    Kim, Hwa Jung
    Kim, Kyu-pyo
    Kim, Sun Young
    Lim, Seok-Byung
    Park, In Ja
    Kim, Chan Wook
    Yoon, Yong Sik
    Yu, Chang Sik
    Kim, Jin Cheon
    Kim, Ji Hun
    Kim, Tae Won
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (05) : 1289 - 1294
  • [10] Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer
    YAO Yang SUN Yuanjue ZHAO Hui GUO Yuewu LIN Feng CAI Xun TANG Xiaochun TANG Lina and ZHANG Wei Department of Oncology Shanghai Sixth Peoples Hospital of Shanghai Jiaotong University Shanghai China Department of Epidemiology Cancer Research Institute of Shanghai Jiaotong University Shanghai China
    ChineseMedicalJournal, 2006, (21) : 1829 - 1833
12345